-transparent.png){kind=logo}
A Phase II trial of an intravenous preparation of Hexamethylmelamine was performed in ovarian cancer. Patients who had received prior Platinum based chemotherapy and had measurable disease were eligible. Among 15 evaluable patients, there were no objective responses. Two patients did show clinical and laboratory evidence of improvement. Toxicity was predominantly nausea and vomiting with minimal other toxicity. This intravenous form of Hexamethylmelamine has not shown meaningful activity in ovarian cancer patients who have failed prior platinum treatment.
Related Publications
M D Hauge, and
H J Long, and
L C Hartmann, and
J H Edmonson, and
M J Webb, and
J Su
February 1979,
Cancer treatment reports,
M D Hauge, and
H J Long, and
L C Hartmann, and
J H Edmonson, and
M J Webb, and
J Su
January 1991,
European journal of cancer (Oxford, England : 1990),
M D Hauge, and
H J Long, and
L C Hartmann, and
J H Edmonson, and
M J Webb, and
J Su
November 1982,
European journal of cancer & clinical oncology,
M D Hauge, and
H J Long, and
L C Hartmann, and
J H Edmonson, and
M J Webb, and
J Su
November 1994,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M D Hauge, and
H J Long, and
L C Hartmann, and
J H Edmonson, and
M J Webb, and
J Su
November 1976,
Cancer treatment reports,
M D Hauge, and
H J Long, and
L C Hartmann, and
J H Edmonson, and
M J Webb, and
J Su
January 1979,
Cancer treatment reports,
M D Hauge, and
H J Long, and
L C Hartmann, and
J H Edmonson, and
M J Webb, and
J Su
January 1993,
Cancer chemotherapy and pharmacology,
M D Hauge, and
H J Long, and
L C Hartmann, and
J H Edmonson, and
M J Webb, and
J Su
June 1984,
American journal of clinical oncology,
M D Hauge, and
H J Long, and
L C Hartmann, and
J H Edmonson, and
M J Webb, and
J Su
August 1986,
Cancer treatment reports,
M D Hauge, and
H J Long, and
L C Hartmann, and
J H Edmonson, and
M J Webb, and
J Su
June 1983,
Cancer treatment reports,
